Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2024-10-16 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, related to dematerialization of securities for the quarter and half year ended September 30, 2024. It is addressed to stock exchanges and confirms compliance with regulatory requirements regarding securities dematerialization and listing. The document is short (3027 characters) and primarily serves as a compliance certificate rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed report content. It is a regulatory compliance certificate submitted to stock exchanges, fitting the category of Regulatory Filings (RNS) as it does not fit other specific categories and is a regulatory compliance document.
2024-10-16 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. It informs about the settlement of a long-pending dispute with Bank of Baroda, the company becoming debt free, and the receipt of a No Dues Certificate. It also mentions legal proceedings withdrawal. The document is an update on a material event related to the company's financial and legal status but does not contain financial statements, detailed financial analysis, or a report. It is a regulatory announcement about a significant corporate event. The document length is short (1789 characters), and it is an announcement rather than a report or detailed filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-10-14 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a consolidated scrutinizer's report on the voting results of the 9th Annual General Meeting (AGM) of Lasa Supergenerics Limited held on September 27, 2024. It includes detailed voting outcomes on various resolutions such as adoption of audited financial statements, appointment of directors, approval of remuneration, and other special resolutions. The document references the AGM, voting procedures, and the results of shareholder votes. It does not contain the full annual report or financial statements themselves but reports on the voting results of the AGM. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a mere announcement of a report but a detailed voting result report.
2024-09-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the closure of the trading window for insiders ahead of the declaration of unaudited financial results for the quarter and half year ended September 30, 2024. It references the upcoming financial results but does not contain any financial data or the results themselves. The document is a regulatory announcement related to insider trading compliance and trading restrictions, not a financial report or earnings release. Given its short length (1636 characters) and nature as an announcement, it fits best under Regulatory Filings (RNS).
2024-09-30 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is titled as a summary of proceedings of the 9th Annual General Meeting (AGM) of LASA Supergenerics Limited held on September 27, 2024. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of meeting proceedings. The content includes details about the meeting date, time, venue (held via video conferencing), attendance, agenda items discussed, resolutions passed, and voting procedures. It also mentions that voting results and scrutinizer's report will be submitted later. The document does not contain full financial statements or detailed financial analysis but is a formal summary of the AGM proceedings. The length is about 7,394 characters, which is consistent with a detailed meeting summary but not a full annual report or financial report. Therefore, this document fits the category of AGM Information (AGM-R).
2024-09-27 English
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the grant of a patent to the company. It is addressed to stock exchanges and is a regulatory announcement about a patent grant, not a financial report or detailed corporate filing. The document length is short (3518 characters) and it does not contain financial data, management discussion, or detailed report content. It is an announcement of a corporate event (patent grant) under regulatory disclosure requirements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.